TY - JOUR T1 - Epidemiological impact of prioritizing SARS-CoV-2 vaccination by antibody status: Mathematical modeling analyses JF - medRxiv DO - 10.1101/2021.01.10.21249382 SP - 2021.01.10.21249382 AU - Houssein H. Ayoub AU - Hiam Chemaitelly AU - Monia Makhoul AU - Zaina Al Kanaani AU - Einas Al Kuwari AU - Adeel A. Butt AU - Peter Coyle AU - Andrew Jeremijenko AU - Anvar Hassan Kaleeckal AU - Ali Nizar Latif AU - Riyazuddin Mohammad Shaik AU - Hanan F. Abdul Rahim AU - Gheyath K. Nasrallah AU - Hadi M. Yassine AU - Mohamed G. Al Kuwari AU - Hamad Eid Al Romaihi AU - Mohamed H. Al-Thani AU - Roberto Bertollini AU - Abdullatif Al Khal AU - Laith J. Abu Raddad Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/12/2021.01.10.21249382.abstract N2 - Background Vaccines against SARS-CoV-2 have been developed, but their availability falls far short of global needs. This study aimed to investigate the impact of prioritizing available doses on the basis of recipient antibody status, that is by exposure status, using Qatar as an example.Methods Vaccination impact was assessed under different scale-up scenarios using a deterministic meta-population mathematical model describing SARS-CoV-2 transmission and disease progression in the presence of vaccination.Results For a vaccine that protects against infection with an efficacy of 95%, half as many vaccinations were needed to avert one infection, disease outcome, or death by prioritizing antibody-negative individuals for vaccination. Prioritization by antibody status reduced incidence at a faster rate and led to faster elimination of infection and return to normalcy. Further prioritization by age group amplified the gains of prioritization by antibody status. Gains from prioritization by antibody status were largest in settings where the proportion of the population already infected at the commencement of vaccination was 30-60%, which is perhaps where most countries will be by the time vaccination programs are up and running. For a vaccine that only protects against disease and not infection, vaccine impact was reduced by half, whether this impact was measured in terms of averted infections or disease outcomes, but the relative gains from using antibody status to prioritize vaccination recipients were similar.Conclusions Major health, societal, and economic gains can be achieved more quickly by prioritizing those who are antibody-negative while doses of the vaccine remain in short supply.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis publication was made possible by NPRP grant number 9-040-3-008 and NPRP grant number 12S-0216-190094 from the Qatar National Research Fund (a member of the Qatar Foundation; https://www.qnrf.org). The statements made herein are solely the responsibility of the authors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available within the manuscript and its supplementary materials. ER -